

### Accurate, Prompt Diagnosis of AHP is Essential to Reduce the Risk of Serious Chronic and Acute Disease Complications<sup>1,2</sup>



Note that not all patients will appear with severe diffuse abdominal pain.<sup>3</sup>

#### Once suspected, appropriate testing can help diagnose AHP<sup>2</sup>



\*Hypothetical case; <sup>†</sup>Urine total porphyrins are not recommended as a screening test for AHP. Testing is most informative if done while patients are symptomatic;<sup>4</sup> <sup>‡</sup>During acute attacks, both ALA and PBG are elevated at least 5-fold the ULN;<sup>4</sup> <sup>§</sup>If only ALA is elevated, check lead levels and urine organic acids to rule out lead poisoning and hereditary tyrosinemia.<sup>4</sup>

Click for abbreviations and references

Intended for US HCPs Scan the QR code to learn more on the RNAi Science website



This resource provides information about AHP, is intended to support scientific exchange, and is not intended as recommendations for clinical practice. For additional scientific information related to Alnylam therapeutic areas, visit the Alnylam US Medical Affairs website at <u>RNAiScience.com</u> to learn more

 $(\mathbf{+})$ 

(+)


(+)

4

Click on



### Consider AHP in Any Patient, Especially Any Woman of Childbearing Age, Who Presents with Unexplained Recurrent, Severe Abdominal Pain<sup>4,\*</sup>



#### **Patient Profile**

Age of onset of clinical manifestation varies, but the majority of patients are aged 15–50 years at onset<sup>4,8</sup>

Women are predominantly affected<sup>4,9</sup>

\*Note that not all patients will appear with severe diffuse abdominal pain.<sup>3</sup>

~1 in 1600–1700 Mutation prevalence of the most common type of AHP, AIP<sup>10,11</sup>

~1% Estimated phenotypic penetrance of symptomatic disease among AIP gene carriers<sup>4</sup> >

~10 in 1,000,000 People diagnosed with symptomatic AIP in the US<sup>12</sup>






AHP is characterized by chronic symptoms, acute attacks, and long-term complications<sup>13-16</sup>

As a multi-system disease, AHP does not fall under the responsibility of a single medical specialty<sup>1</sup>

Pick your speciality to learn more about the common presenting symptoms of AHP:





#### Symptoms experienced by patients with AHP\*,<sup>†</sup>

#### **Gastrointestinal symptoms**

- ✓ Nausea
- Constipation
- ✓ Loss of appetite
- ✓ Vomiting<sup>A</sup>
- Heartburn

#### **Pain symptoms**

✓ Abdominal pain

<sup>A</sup>Acute symptom only; <sup>C</sup>Chronic symptom only.

All symptoms can be both acute and chronic unless otherwise stated.

- Arm/leg pain
- Back pain
- Muscle pain
- Headache
- Other pain

#### Mood or sleep symptoms

#### ✓ Tiredness

- □ Trouble sleeping
- Anxiety
- Trouble concentrating
- □ Feeling unmotivated<sup>C</sup>
- Hallucinations

#### **Other symptoms**

- ✓ Changes in urine color
- Weakness
- Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- Blisters/rashes

#### **Hepatologist**

As a hepatologist, consider symptoms of **hepatic disorder** in **blue** in your patients that may be suggestive of AHP

Take a moment to consider the other symptoms of AHP:

- Does your patient have any other symptoms that match the AHP symptom profile?
- Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a differential diagnosis

> **Click for abbreviations** and references



#### Symptoms experienced by patients with AHP\*, †

#### **Gastrointestinal symptoms**

- Nausea
- Constipation
- Loss of appetite
- Uvoniting<sup>A</sup>
- Heartburn

#### Pain symptoms

- Abdominal pain
- Arm/leg pain
- Back pain
- Muscle pain
- Headache
- Other pain

#### Mood or sleep symptoms

- Tiredness
- □ Trouble sleeping
- Anxiety
- Trouble concentrating
- □ Feeling unmotivated<sup>c</sup>
- □ Hallucinations

#### Other symptoms

- Changes in urine color
- U Weakness
- Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- □ Blisters/rashes

All symptoms can be both acute and chronic unless otherwise stated. <sup>A</sup>Acute symptom only; <sup>c</sup>Chronic symptom only.

#### Hematologist

As a hematologist, consider **symptoms** in your patients that may be **suggestive of AHP** 

• Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a **differential diagnosis** 





#### Symptoms experienced by patients with AHP\*,<sup>†</sup>

#### **Gastrointestinal symptoms**

- ✓ Nausea
- ✓ Constipation
- ✓ Loss of appetite
- ✓ Vomiting<sup>A</sup>
- ✓ Heartburn

#### Pain symptoms

- Abdominal pain
- Arm/leg pain
- Back pain
- Muscle pain
- Headache
- Other pain

#### Mood or sleep symptoms

- Tiredness
- □ Trouble sleeping
- Anxiety
- Trouble concentrating
- □ Feeling unmotivated<sup>c</sup>
- □ Hallucinations

#### Other symptoms

- □ Changes in urine color
- Weakness
- Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- Blisters/rashes

All symptoms can be both acute and chronic unless otherwise stated. <sup>A</sup>Acute symptom only; <sup>c</sup>Chronic symptom only.



#### Gastroenterologist

As a gastroenterologist, consider **GI symptoms** in **blue** in your patients that may be **suggestive of AHP** 

Take a moment to consider **the other** symptoms of AHP:

- Does your patient have any other symptoms that match the AHP symptom profile?
- Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a **differential diagnosis** 





#### Symptoms experienced by patients with AHP\*,<sup>†</sup>

#### **Gastrointestinal symptoms**

- Nausea
- Constipation
- Loss of appetite
- U Vomiting<sup>A</sup>
- Heartburn

#### **Pain symptoms**

- ✓ Abdominal pain
- ✓ Arm/leg pain
- ✓ Back pain
- ✓ Muscle pain
- ✓ Headache

✓ Other pain

<sup>A</sup>Acute symptom only; <sup>C</sup>Chronic symptom only.

All symptoms can be both acute and chronic unless otherwise stated.

#### Mood or sleep symptoms

- ✓ Tiredness
- ✓ Trouble sleeping
- ✓ Anxiety
- ✓ Trouble concentrating
- ✓ Feeling unmotivated<sup>c</sup>
- ✓ Hallucinations

#### **Other symptoms**

- □ Changes in urine color
- U Weakness
- ✓ Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- Blisters/rashes



#### Neurologist

As a neurologist, consider **neurological symptoms** in **blue** in your patients that may be **suggestive of AHP** 

Take a moment to consider **the other** symptoms of AHP:

- Does your patient have any other symptoms that match the AHP symptom profile?
- Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a **differential diagnosis** 

**+** Click for abbreviations and references



#### Symptoms experienced by patients with AHP\*,<sup>†</sup>

#### **Gastrointestinal symptoms**

All symptoms can be both acute and chronic unless otherwise stated.

<sup>A</sup>Acute symptom only; <sup>C</sup>Chronic symptom only.

- Nausea
- Constipation
- Loss of appetite
- U Vomiting<sup>A</sup>
- Heartburn

#### **Pain symptoms**

- Abdominal pain
- Arm/leg pain
- Back pain
- Muscle pain
- Headache
- Other pain

#### Mood or sleep symptoms

- ✓ Tiredness
- ✓ Trouble sleeping
- ✓ Anxiety
- ✓ Trouble concentrating
- ✓ Feeling unmotivated<sup>c</sup>
- ✓ Hallucinations

#### **Other symptoms**

- Changes in urine color
- Weakness
- Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- □ Blisters/rashes



#### **Psychiatrist**

As a psychiatrist, consider **psychological** symptoms in blue in your patients that may be suggestive of AHP

Take a moment to consider **the other** symptoms of AHP:

- Does your patient have any other symptoms that match the AHP symptom profile?
- Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a differential diagnosis

> **Click for abbreviations** and references



#### Symptoms experienced by patients with AHP\*,<sup>†</sup>

#### **Gastrointestinal symptoms**

- Nausea
- Constipation
- Loss of appetite
- Uvoniting<sup>A</sup>
- Heartburn

#### **Pain symptoms**

- Abdominal pain
- Arm/leg pain
- Back pain
- Muscle pain
- Headache
- Other pain

#### Mood or sleep symptoms

- Tiredness
- □ Trouble sleeping
- Anxiety
- Trouble concentrating
- □ Feeling unmotivated<sup>C</sup>
- Hallucinations

#### Other symptoms

- □ Changes in urine color
- Weakness
- Numbness
- Fast heartbeat
- Sweating<sup>A</sup>
- □ Blisters/rashes

All symptoms can be both acute and chronic unless otherwise stated. <sup>A</sup>Acute symptom only; <sup>C</sup>Chronic symptom only.



#### **Identifying Symptoms**


Consider **symptoms** in your patients that may be **suggestive of AHP** 

• Does your patient fit the AHP patient profile?

If yes, consider testing for AHP as a **differential diagnosis** 



### AHP Arises from Genetic Variants that Disrupt the Heme Biosynthesis Pathway







## Characteristics of AHP Types

AHP Type <sup>21</sup>	Sex <sup>21</sup>	Age of Onset	Typical Presenting Symptoms <sup>21</sup>		Estimated % of AHP
			Acute Attacks	Cutaneous	% 01 AHP
AIP	Symptomatic patients are predominantly female <sup>21–23</sup>	15–50 years <sup>4,8</sup>	~		Most prevalent ~80% <sup>5</sup>
VP			~	~	Less prevalent <sup>24</sup>
НСР			~	~	Less prevalent <sup>24</sup>
ADP	All recorded symptomatic patients have been male <sup>21</sup>	Variable <sup>19</sup>	~		<b>Least prevalent</b> 12 cases ever reported worldwide <sup>25</sup>







## Delayed Diagnosis Can Negatively Impact Patient Morbidity and Mortality



Patients often **present to emergency departments** where less common causes of typical AHP presenting symptoms (e.g. abdominal pain) are often not considered<sup>1</sup>

> "Very few doctors understand what porphyria is or even how to treat it" *Patient with AHP*<sup>5</sup>

Patients report **frequent hospitalizations and visits to multiple specialists before diagnosis,** with many being labelled as "drug seekers" because of their recurrent need for pain relief<sup>2</sup>

"I have to take all these stupid medications, and there's so much stigma in society about prescription pain meds" *Patient with AHP*<sup>5</sup>



Many patients experience delays in diagnosis or misdiagnosis, resulting in **inappropriate or harmful treatments**, including certain medications that can upregulate the heme biosynthesis pathway and **worsen AHP symptoms**<sup>1</sup>

Inaccurate diagnoses may also result in **ineffective surgical interventions**, for example appendectomy or hysterectomy<sup>4</sup>



Patients with AHP Can Experience an Array of Chronic Symptoms, Which Fluctuate in Severity, Alongside Acute Attacks Resulting in Hospitalization Which Leads to High Disease Burden<sup>3,5</sup>



65% of patients with recurrent attacks experience chronic symptoms, most commonly pain, tiredness, anxiety, and nausea, with 46% of patients experiencing these symptoms daily<sup>3,\*</sup> "When it's chronic, it's something I'm constantly having to manage... there will be pains where I feel like I'm getting stung by a swarm of bees or something like that. But it doesn't get to the point where I'm having to go to the emergency room and vomiting"<sup>5</sup>



Click to learn more about the longterm complications of AHP that add to disease burden





\*EXPLORE-A (N=112) included patients who had 3 attacks or more or were receiving prophylactic treatment.<sup>3</sup>

Delayed Diagnosis Can Lead to the Development of Serious Long-Term Complications Which Add to the Disease Burden Experienced by Patients with AHP

#### Long-term complications of AHP

#### **Primary liver cancer**

- Hepatoma should be considered if a patient develops abdominal pain after long-term remission<sup>19</sup>
- A Norwegian registry cohort study found the risk of **primary liver cancer** was 108-fold III higher over the lifetime of patients with AHP (n=251) versus controls<sup>26</sup>

#### **Chronic sustained hypertension**

 Hypertension is more prevalent among patients with AIP compared with the general population<sup>19</sup>



#### **Chronic kidney disease**

- ALA and PBG have potential nephrotoxic effects, leading to oxidative stress and tissue injury<sup>27</sup>
- Repeated AHP attacks lead to acute kidney injury<sup>27</sup>



 Both experimental and clinical data demonstrated that ALA accumulation has highly neurotoxic effects, responsible for **neuropathy** and axonal degeneration via multiple proposed mechanisms<sup>28,29</sup>







## Practical Guidance for Measuring PBG and ALA

## Substantial elevation of urine PBG and ALA is a distinctive biochemical feature of AHP, and therefore, a key diagnostic tool<sup>4</sup>


Ordering tests	Analyzing results	Considerations
<ul> <li>Porphyrin tests do not include ALA and PBG, as they are porphyrin precursors<sup>4</sup></li> <li>It is key to request the correct test to ensure informative results are obtained<sup>1,7</sup></li> </ul>	<ul> <li>Substantial PBG elevation has a high degree of specificity and sensitivity for AIP, VP, or HCP because an elevation many times above normal does not occur in any other medical condition<sup>1</sup></li> <li>ALA elevation is indicative of the ultra-rare AHP subtype ADP, in which PBG levels are normal or only slightly elevated<sup>1</sup></li> <li>ALA and PBG excretion should be normalized to creatinine to adjust for differences in the degree of urinary concentration<sup>4</sup></li> <li>The ULN for ALA and PBG are 1.47 and 0.137 mmol/mol Cr, respectively<sup>30</sup></li> </ul>	<ul> <li>Both ALA and PBG can be measured with high sensitivity and specificity, but both often require large reference laboratories and results can take 1-2 weeks to be reported<sup>4</sup></li> <li>Despite challenges, it is important to test for ALA and PBG as biochemical testing is required for AHP diagnosis<sup>4</sup></li> </ul>

(





ALA and PBG Levels Can Vary Depending on AHP Type and Timing of Measurement, Therefore Repeat Testing May be Required for a Diagnosis



## Genetic Counselling is Recommended for Patients and Carriers<sup>4</sup>

Genetic testing of the 4 genes *ALAD*, *HMBS*, *CPOX*, and *PPOX* leads to ADP, AIP, HCP, and VP diagnosis, respectively

Although genetic testing can confirm a diagnosis, it is **not recommended for initial screening**  This is because the estimated phenotypic
penetrance of symptomatic disease is approximately 1% of AIP gene carriers

This increases to >20% in families of symptomatic patients



Once the familial pathogenic variant has been identified in the patient, **first-degree family members should be screened** to identify at-risk patients. Those who are mutation carriers should receive genetic counselling





### **Abbreviations and References**

A, acute; ADP, ALA dehydratase-deficient porphyria; AHP, acute hepatic porphyria; ALAD, aminolevulinate dehydratase; ALAS1, ALA synthase 1; AIP, acute intermittent porphyria; ALA, δ-aminolevulinic acid; C, chronic; Cr, creatinine; CoA, coenzyme A; CPOX, coproporphyrinogen oxidase; CYP450, cytochrome P450, HCP, hereditary coproporphyria; HMBS, hydroxymethylbilane synthase; PBG, porphobilinogen; PPOX, protoporphyrinogen oxidase; ULN, upper limit of normal; VP, variegate porphyria.

- 1. Anderson KE, et al. *Am J Med Sci* 2021;362:113–121.
- 2. Anderson KE, et al. *Am J Med Sci* 2022;363:1–10.
- 3. Gouya L et al. *Hepatology* 2020;71:1546–1558.
- 4. Wang B, et al. *Gastroenterology* 2023;164:484–491.
- 5. Simon A, et al. *Patient* 2018;11:527–537.
- 6. Bonkovsky HL, et al. *Am J Med* 2014;127:1233–1241.
- 7. Thapar M, et al. *Clin Exp Gastroenterol* 2024;17:1–8.
- 8. Bissel DM & Wang B. *J Clin Transl Hepatol* 2015;3:17–26.
- 9. Bissel DM et al. *N Engl J Med* 2017;377:862–872.
- 10. Nordmann Y et al. *J Intern Med* 1997;242:213–217.
- 11. Chen B et al. *Hum Mutat* 2016;37:1215–1222.
- 12. Silver SM et al. Presented at the American College of Gastroenterology Scientific Meeting. October 25–29, 2019, San Antonio, TX, USA.
- 13. Wheeden K et al. *Adv Ther* 2022;39:4330–4345.
- 14. Dickey A et al. *JIMD Rep* 2022;64:104–113.
- 15. Cassiman D, et al. *J Inherit Metab Dis* 2022;45:1163–1174.
- 16. Pischik E, et al. *Liver Int* 2024;44:2197–2207.

- 17. Balwani M et al. *Hepatology* 2017;66:1314–1322.
- 18. Besur et al. *Metabolites* 2014;4:977–1006.
- 19. Pischik E & Kauppinen R. *Appl Clin Genet* 2015;8:201–214.
- 20. Ventura et al. *Eur J Intern Med* 2014;25:497–505.
- 21. Ramanujam VMS & Anderson KE. *Curr Protoc Hum Genet* 2015;86:17.20.1–17.20.26.
- 22. NORD. Variegate porphyria Affected Populations. Available at: https://rarediseases.org/rarediseases/variegate-porphyria/#affected (accessed October 2024).
- 23. Sam SS et al. *J Hematol* 2016;5:67–69.
- 24. Elder G et al. *J Inherit Metab Dis* 2013;36:849–857.
- 25. Syed YY. *Drugs* 2021;81:841–848.
- 26. Baravelli CM et al. *J Intern Med* 2017;282:229–240.
- 27. Pallet N et al. *Clin Kidney J* 2018; 11:191–197.
- 28. Felitsyn N et al. *J Neurochem* 2008;106:2068–2079.
- 29. Meyer UA et al. *Semin Liver Dis* 1998;18:43–52.
- 30. Agarwal S et al. *JIMD Rep* 2020;57:85–93.